Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients

Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, Sacchi Samantha Pozzi, Angela Ferrari, Luca Baldini, Paolo Gobbi, Ariel Aviv, Giuseppe Pugliese, Massimo Federico, Aaron Polliack, Stefano Sacchi

Research output: Contribution to journalArticle

Abstract

Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression-free survival and overall survival compared to those with NLR ≤6; 84% vs 75% and 92% vs 88%, at 5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk remained high with HR 1.44 and HR 1.54 in progression-free survival and overall survival, respectively. In summary, our study shows that NLR is a robust and independent prognostic parameter in NS-cHL, both in early and advanced disease. It is inexpensive and simple to apply. Thus, we conclude that NLR, possibly in combination with the international prognostic score and absolute monocyte count, is a useful guide for physicians treating NS-cHL patients.

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusE-pub ahead of print - Oct 28 2016

Fingerprint

Sclerosis
Hodgkin Disease
Multicenter Studies
Neutrophils
Lymphocytes
Disease-Free Survival
Survival
Non-Hodgkin's Lymphoma
Monocytes
Multivariate Analysis
Physicians
Neoplasms

Keywords

  • Journal Article

Cite this

Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma : results of a large multicenter study involving 990 patients. / Marcheselli, Raffaella; Bari, Alessia; Tadmor, Tamar; Marcheselli, Luigi; Cox, Maria Christina; Pozzi, Sacchi Samantha; Ferrari, Angela; Baldini, Luca; Gobbi, Paolo; Aviv, Ariel; Pugliese, Giuseppe; Federico, Massimo; Polliack, Aaron; Sacchi, Stefano.

In: Hematological Oncology, 28.10.2016.

Research output: Contribution to journalArticle

Marcheselli, Raffaella ; Bari, Alessia ; Tadmor, Tamar ; Marcheselli, Luigi ; Cox, Maria Christina ; Pozzi, Sacchi Samantha ; Ferrari, Angela ; Baldini, Luca ; Gobbi, Paolo ; Aviv, Ariel ; Pugliese, Giuseppe ; Federico, Massimo ; Polliack, Aaron ; Sacchi, Stefano. / Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma : results of a large multicenter study involving 990 patients. In: Hematological Oncology. 2016.
@article{b93089da5d934235afb8b7a8f74e57a2,
title = "Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients",
abstract = "Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression-free survival and overall survival compared to those with NLR ≤6; 84{\%} vs 75{\%} and 92{\%} vs 88{\%}, at 5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk remained high with HR 1.44 and HR 1.54 in progression-free survival and overall survival, respectively. In summary, our study shows that NLR is a robust and independent prognostic parameter in NS-cHL, both in early and advanced disease. It is inexpensive and simple to apply. Thus, we conclude that NLR, possibly in combination with the international prognostic score and absolute monocyte count, is a useful guide for physicians treating NS-cHL patients.",
keywords = "Journal Article",
author = "Raffaella Marcheselli and Alessia Bari and Tamar Tadmor and Luigi Marcheselli and Cox, {Maria Christina} and Pozzi, {Sacchi Samantha} and Angela Ferrari and Luca Baldini and Paolo Gobbi and Ariel Aviv and Giuseppe Pugliese and Massimo Federico and Aaron Polliack and Stefano Sacchi",
note = "{\circledC} 2016 The Authors Hematological Oncology Published by John Wiley & Sons Ltd.",
year = "2016",
month = "10",
day = "28",
doi = "10.1002/hon.2359",
language = "English",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",

}

TY - JOUR

T1 - Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma

T2 - results of a large multicenter study involving 990 patients

AU - Marcheselli, Raffaella

AU - Bari, Alessia

AU - Tadmor, Tamar

AU - Marcheselli, Luigi

AU - Cox, Maria Christina

AU - Pozzi, Sacchi Samantha

AU - Ferrari, Angela

AU - Baldini, Luca

AU - Gobbi, Paolo

AU - Aviv, Ariel

AU - Pugliese, Giuseppe

AU - Federico, Massimo

AU - Polliack, Aaron

AU - Sacchi, Stefano

N1 - © 2016 The Authors Hematological Oncology Published by John Wiley & Sons Ltd.

PY - 2016/10/28

Y1 - 2016/10/28

N2 - Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression-free survival and overall survival compared to those with NLR ≤6; 84% vs 75% and 92% vs 88%, at 5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk remained high with HR 1.44 and HR 1.54 in progression-free survival and overall survival, respectively. In summary, our study shows that NLR is a robust and independent prognostic parameter in NS-cHL, both in early and advanced disease. It is inexpensive and simple to apply. Thus, we conclude that NLR, possibly in combination with the international prognostic score and absolute monocyte count, is a useful guide for physicians treating NS-cHL patients.

AB - Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non-Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was to establish whether NLR could serve as an independent prognostic factor in a cohort of 990 patients with nodular sclerosis (NS)-cHL. After analysis of the log hazard ratio (HR) as a function of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression-free survival and overall survival compared to those with NLR ≤6; 84% vs 75% and 92% vs 88%, at 5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk remained high with HR 1.44 and HR 1.54 in progression-free survival and overall survival, respectively. In summary, our study shows that NLR is a robust and independent prognostic parameter in NS-cHL, both in early and advanced disease. It is inexpensive and simple to apply. Thus, we conclude that NLR, possibly in combination with the international prognostic score and absolute monocyte count, is a useful guide for physicians treating NS-cHL patients.

KW - Journal Article

U2 - 10.1002/hon.2359

DO - 10.1002/hon.2359

M3 - Article

C2 - 27791277

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -